Dihexa
More than 3 million people with Medicare could be eligible for the difficult-to-find and expensive weight-loss drug under new guidance which can cover the medication for patients who are obese or those who have a history of heart disease and are at risk of a heart attack or stroke
This can help maintain the effectiveness of GLP-1 medications over time and support better overall health outcomes.
The problem with sermorelin is its size
MDPI Hoteit BH, et al
15 Cancers GLP-1s have been investigated for their impact in reducing the risk of obesity-related cancers (OACs) such as colorectal cancer, esophageal, breast, colorectal, endometrial, gallbladder, stomach, kidney, ovarian, pancreatic, and thyroid cancer, as well as hepatocellular carcinoma, meningioma, and multiple myeloma